TITLE

Diabetik Retinopatide Güncel Tıbbi Tedavi Yaklaşımları

AUTHOR(S)
Polat, Burcu; Batioğlu, Figen
PUB. DATE
September 2007
SOURCE
Retina-Vitreus/Journal of Retina-Vitreous;Sep2007, Vol. 15 Issue 3, p153
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Diabetic retinopathy (DR) is one of the most important causes of blindness in developed societies. The risk of complications increases by the duration of disease and some coexisting systemic disorders affect the progression. Therefore, first step in the treatment of DR is regulation of systemic risk factors. Although laser photocoagulation and vitreoretinal surgery are the main treatment modalities of DR, medical approaches have advanced, currently. Antioxidants, inhibitors of aldose reductase, advanced glycation end products, protein kinase C and vascular endothelial growth factor (VEGF) inhibitors and intravitreal corticosteroid injections are medical treatment modalities of DR. The advances in medical approaches can retard the development and progression of DR. In this study, new medical treatment approaches were discussed with the review of recent literature.
ACCESSION #
27694631

 

Related Articles

  • Fluocinolone Acetonide Intravitreal Implant (Iluvien). Sanford, Mark // Drugs;2013, Vol. 73 Issue 2, p187 

    Fluocinolone acetonide intravitreal implant (Iluvien) is an injectable, non-erodible, corticosteroid implant that is approved in several European countries for the treatment of chronic diabetic macular oedema (DMO). In analyses of two multinational trials in patients with DMO previously treated...

  • Purtscher retinopathies: Are we aiming at the wrong target? Yusuf, I H; Watson, S-L // Eye;Jun2013, Vol. 27 Issue 6, p783 

    A letter to the editor is presented in response to the article "Systematic review of Purtscher's and Purtscher-like retinopathies," by A.I. Miguel and colleagues.

  • Fluocinolone Acetonide Implantable Device for Diabetic Retinopathy. Schwartz, Stephen G.; Flynn Jr., Harry W. // Current Pharmaceutical Biotechnology;Mar2011, Vol. 12 Issue 3, p347 

    No abstract available.

  • Optical coherence tomography-guided selective focal laser photocoagulation: a novel laser protocol for diabetic macular edema. Shin, Joo; Byeon, Suk; Kwon, Oh // Graefe's Archive of Clinical & Experimental Ophthalmology;Apr2015, Vol. 253 Issue 4, p527 

    Background: To compare the anatomic and functional results between optical coherence tomography (OCT)-guided selective focal laser photocoagulation (OCT-laser) and conventional modified Early Treatment Diabetic Retinopathy Study (mETDRS) laser treatment for diabetic macular edema (DME). Methods:...

  • Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion. Unsal, Erkan; Eltutar, Kadir; Sultan, Pınar; Gungel, Hulya // Pakistan Journal of Medical Sciences;May/Jun2015, Vol. 31 Issue 3, p510 

    Objectives: To evaluate the effects and safety of intravitreal ranibizumab on visual acuity and anatomic results in the treatment of macular edema due to retinal vein occlusion (RVO). Methods: Forty Six eyes of 45 patients who were administered intravitreal ranibizumab because of macular edema...

  • Advances in the Medical Treatment of Diabetic Retinopathy. Simó, Rafael; Hernández, Cristina // Diabetes Care;Aug2009, Vol. 32 Issue 8, p1556 

    The article focuses on the advances made in relation to the medical treatment of diabetic retinopathy. It notes that proliferative diabetic retinopathy (PDR) stands as the leading cause of blindness among the working-age population in developed nations while diabetic macular edema (DME) is more...

  • Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. Augustin, Albert J.; Kuppermann, Baruch D.; Lanzetta, Paolo; Loewenstein, Anat; Xiao-Yan Li; Cui, Harry; Hashad, Yehia; Whitcup, Scott M.; Li, Xiao-Yan; Ozurdex MEAD Study Group // BMC Ophthalmology;10/30/2015, Vol. 15, p1 

    Background: Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup analysis of MEAD study results to evaluate the efficacy...

  • New Approaches to Diabetic Retinopathy. Murphy, Rob // Review of Ophthalmology;Aug2002, Vol. 9 Issue 8, p47 

    Presents several approaches to diabetic retinopathy. Effectiveness of photocoagulation in treating focal areas of macular edema; Reduction of retinal thickness in intravitreal corticosteroid; Tendency of PKC beta inhibitors to ameliorate diabetic vascular complications.

  • Revolution to a New Standard Treatment of Diabetic Macular Edema. Jampol, Lee M.; Bressler, Neil M.; Glassman, Adam R. // JAMA: Journal of the American Medical Association;6/11/2014, Vol. 311 Issue 22, p2269 

    The authors comment on the revolution of a new standard treatment for diabetic macular edema (DME) since 2001, including intravitreal injections of corticosteroids as an alternative to laser photocoagulation. Topics covered include a study which compared the efficacy of anti-vascular endothelial...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics